Advertisement
Steve Worland, Ph.D., President and Chief Executive Officer of AnadysPharmaceuticals, Inc., will present an overview of Anadys and an update onANA598, its development-stage product candidate for the treatment of chronichepatitis C.
Advertisement
The presentation will be simultaneously webcast and can be accessed on theInvestor Relations page of the Company's website athttp://www.anadyspharma.com. Listeners are encouraged to visit the websiteapproximately five minutes prior to the presentation to download or installany necessary software. A replay of the presentation will be availableapproximately one hour after the live webcast concludes and will be availablethrough April 23, 2008.
About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated toimproving patient care by developing novel medicines in the areas of hepatitisC and oncology. The Company is developing ANA598, a small-molecule,non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronichepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical innature constitute "forward-looking statements." Such statements include, butare not limited to, references to Anadys' strategy, development programs, andability to develop novel medicines in the areas of hepatitis C and oncology.Such forward-looking statements involve known and unknown risks, uncertaintiesand other factors, which may cause Anadys' actual results to be materiallydifferent from historical results or from any results expressed or implied bysuch forward-looking statements. For example, the results of preclinicalstudies may not be predictive of future results, and Anadys cannot provide anyassurances that ANA598 or ANA773 will not have unforeseen safety issues, willhave favorable results in future clinical trials or will receive regulatoryapproval. Risk factors that may cause actual results to differ are discussedin Anadys' SEC filings, including Anadys' Form 10-K for the year endedDecember 31, 2007. All forward-looking statements are qualified in theirentirety by this cautionary statement. Anadys is providing this informationas of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information,future events or otherwise.
SOURCE Anadys Pharmaceuticals, Inc.
